Road Rage Shooting

Showing 3825 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Enova International Posts Strong 2025 Results Fueled by Lending Growth and Buybacks, But High Leverage Raises Questions

Enova International reports robust revenue and earnings growth for Q4 and full-year 2025, driven by expansion in its consumer and small business lending segments and a significant share repurchase program. While the financial technology lender's machine-learning underwriting and capital returns strategy have rewarded shareholders, analysts point to its elevated debt load and exposure to economic cycles as key areas for investor scrutiny.

Business

Villars Holding Sees Uptick in Capital Efficiency, Sparking Investor Interest

The Swiss retailer Villars Holding (VTX:VILN) is showing promising signs of improved capital allocation, with its return on capital employed (ROCE) rising significantly over the past five years alongside increased investment. While its overall return remains below the industry average, the positive trajectory suggests potential for a turnaround.